REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Nov 26, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-11-21

Reporting Person: Terifay Robert J (SVP Commercial)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-11-21	Common Stock	M	20000.0	$16.8	Acquired	29372.0	Direct
2012-11-21	Common Stock	F	1932.0	$173.83	Disposed	27440.0	Direct
2012-11-21	Common Stock	F	8323.0	$173.83	Disposed	19117.0	Direct
2012-11-23	Common Stock	S	1000.0	$173.9	Disposed	18117.0	Direct
2012-11-23	Common Stock	S	6700.0	$174.33	Disposed	11417.0	Direct
2012-11-23	Common Stock	S	2045.0	$175.09	Disposed	9372.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-11-21	Non-Qualified Stock Option (right to buy)	$16.8	M	20000.0	Disposed	2018-12-17	Common Stock (20000.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1531.0	Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 1,000 shares of Company stock on November 23, 2012 at prices ranging from $173.90 to $173.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2012 at each separate price.

F2: Represents volume-weighted average price of sales of 6,700 shares of Company stock on November 23, 2012 at prices ranging from $174.00 to $174.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 2,045 shares of Company stock on November 23, 2012 at prices ranging from $175.00 to $175.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2012 at each separate price.

F4: The option became exercisable with respect to all shares underlying the option on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011.

F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.